Drug Profile
Research programme: autoimmune disorder therapeutics - Axxam
Alternative Names: ICRAC blocker - Axxam; Kv1.3 blocker - Axxam; P2X7 blocker - AxxamLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Axxam
- Class
- Mechanism of Action Kv1.3 potassium channel inhibitors; ORAI1 protein inhibitors; Purinergic P2X7 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Autoimmune disorders; Multiple sclerosis; Type 1 diabetes mellitus
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Autoimmune-disorders in Italy
- 16 Jul 2016 No recent reports of development identified for research development in Multiple-sclerosis in Italy
- 16 Jul 2016 No recent reports of development identified for research development in Type-1 diabetes mellitus in Italy